Status:
RECRUITING
NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals
Lead Sponsor:
Haukeland University Hospital
Collaborating Sponsors:
University of Bergen
Conditions:
Sleep
Eligibility:
All Genders
40-60 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is...
Detailed Description
Nicotinamide adenine dinucleotide (NAD+) is important for regulating cellular energy metabolism, mitochondrial function, and circadian rhythms, which are key processes involved in the sleep-wake cycle...
Eligibility Criteria
Inclusion
- Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent.
- Male or female.
- Participants who are healthy as determined by medical evaluation including medical history and physical examination.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol.
- Self-reported normal sleep patterns, assessed by Pittsburgh sleep quality index (PSQI; cutoff ≤ 5).
- No current use of sleep medications or supplements.
- Able to wear polysomnographic equipment and actigraphy during nighttime.
Exclusion
- History of sleep disorders (e.g. insomnia, sleep apnea).
- Abnormal findings on PSG, such as sleep related breathing disorders (apnea-hypopnea index (AHI) ≥ 5), sleep related movement disorders (periodic limb movement index (PLMI) ≥ 15, and parasomnias (like REM sleep behavior disorder (RBD)).
- Chronic use of alcohol, tobacco, or medications affecting sleep.
- Significant psychiatric or medical conditions (including neurological, heart, lung, or sleep disorders/diseases).
- Travelled \>1 time zone and night work \<1 month before study, or during the study.
- Extreme chronotype according to the Composite Morningness Questionnaire (evening type; \<22 and morning type \>44).
- Pregnancy.
- Breastfeeding.
- Supplements resulting in \> 20 mg daily of nicotinamide riboside, nicotinamide mononucleotide (NMN), niacin (vitamin B3, nicotinic acid amide or other vitamin B3 analogues) less than 3 months prior to randomization.
- Participation in other clinical trials last 3 months.
- Deemed ineligible by lead principal investigator.
Key Trial Info
Start Date :
October 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06971224
Start Date
October 13 2025
End Date
June 1 2026
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital
Bergen, Norway